Lexon is developing the Ebaf Assay product for colon cancer and some forms of testicular and ovarian cancer, says Thomas Coughlin, Lexon's medical director. Doctors routinely perform this kind of test on blood samples taken during physicals. A similar screen for colon cancer would have a market more than twice as large, because it would include women. Right now, the LG Group has five such concerns, including Lexon. The advantage to all schools is UTEK's staff.
Research funding is the primary one.
All rights reserved.